相关文章推荐
考研的围巾  ·  阿尔泰山降水氢氧稳定同位素特征及水汽来源分析·  1 周前    · 
道上混的斑马  ·  臺灣大學數位人文研究中心·  2 天前    · 
不要命的汉堡包  ·  上海交通大学安泰经济与管理学院MBA项目·  5 月前    · 
文质彬彬的野马  ·  如何评价菲利普因扎吉的能力？为什么现在足坛几 ...·  2 年前    · 
怕老婆的米饭  ·  金东区人民政府 历史沿革·  2 年前    · 
坏坏的路灯  ·  跟 Q5 沒關係！上汽奧迪 Audi Q5 ...·  2 年前    · 
朝气蓬勃的李子  ·  海贼王：小丑巴基果实觉醒，取代凯多成为四皇·  2 年前    · 
小百科  ›  抗水通道蛋白4抗体阳性视神经脊髓炎谱系疾病诊断与治疗进展
视神经脊髓炎谱系疾病(NMOSD)666 健康 doi
沉稳的茶壶
2 周前
Supported by:
Cultivation Fund of The Second Hospital of Shandong University(2023YP01); the National Natural Science Foundation of China(82071343); the National Natural Science Foundation of China(82371354); the National Natural Science Foundation of China(81701188); Guangdong Basic and Applied Basic Research Fund(2021A1515010393); Guangzhou Science and Technology Key Research and Development Plan(2023B03J1347); Guangzhou Municipal School (Hospital) Joint Funding(202201020415)

摘要：

视神经脊髓炎谱系疾病（NMOSDs）以抗水通道蛋白4（AQP4）抗体阳性NMOSDs最为多见，主要表现为反复发作的视神经炎和脊髓炎等，严重降低患者生活质量。近年来，对该病的诊断技术、诊断标志物和免疫治疗药物不断有新的认识，本文综述抗AQP4抗体阳性NMOSDs的诊断技术和诊断标志物新进展以及新的治疗药物，以促进对该病的诊断与治疗新技术的理解和应用，探索更多可能的临床诊断与治疗方法。

视神经脊髓炎, 水通道蛋白质4, 免疫疗法,

Abstract:

Neuromyelitis optica spectrum disorders (NMOSDs) are most common in anti -aquaporin 4 (AQP4) antibody positive NMOSDs, which are characterized by recurrent episodes of optic neuritis and myelitis, etc., and severely reduce the quality of life. In recent years, new insights into the diagnostic techniques, diagonstic markers, and immunotherapy of anti-AQP4 antibody positive NMOSDs have continued to emerge, and here we focus on synthesizing new advances in the diagnostic techniques and diagonstic markers of anti-AQP4 antibody positive NMOSDs and the most recent recommendations for its treatment, in hopes of summarizing to promote the understanding and application of new diagnostic and therapeutic techniques for anti-AQP4 antibody positive NMOSDs in China, and to explore more possible clinical diagnostic and therapeutic approaches.

Key words: Neuromyelitis optica, Aquaporin 4, Immunotherapy, Review

许鸿嘉, 舒崖清, 王蘋, 李蕃, 许顺良, 邱伟, 马晓宇. 抗水通道蛋白4抗体阳性视神经脊髓炎谱系疾病诊断与治疗进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 308-314.

Hong-jia XU, Ya-qing SHU, Pin WANG, Fan LI, Shun-liang XU, Wei QIU, Xiao-yu MA. Advances on the diagnosis and treatment of aquaporin 4 antibody positive neuromyelitis optica spectrum disorders[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 308-314.

Bennett JL , O'Connor KC , Bar-Or A , Zamvil SS , Hemmer B , Tedder TF , von Büdingen HC , Stuve O , Yeaman MR , Smith TJ , Stadelmann C . B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm , 2015 , 2 : e104.
doi: 10.1212/NXI.0000000000000104
Neuroimmunology Branch, Chinese Society of Immunology . Diagnosis and treatment guidelines for optic neuromyelitis spectrum diseases in China (2021 edition). Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2021 , 28 : 423- 436.
Jarius S , Paul F , Aktas O , Asgari N , Dale RC , de Seze J , Franciotta D , Fujihara K , Jacob A , Kim HJ , Kleiter I , Kümpfel T , Levy M , Palace J , Ruprecht K , Saiz A , Trebst C , Weinshenker BG , Wildemann B . MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation , 2018 , 15 : 134.
doi: 10.1186/s12974-018-1144-2
Kümpfel T , Giglhuber K , Aktas O , Ayzenberg I , Bellmann-Strobl J , Häußler V , Havla J , Hellwig K , Hümmert MW , Jarius S , Kleiter I , Klotz L , Krumbholz M , Paul F , Ringelstein M , Ruprecht K , Senel M , Stellmann JP , Bergh FT , Trebst C , Tumani H , Warnke C , Wildemann B , Berthele A , Neuromyelitis Optica Study Group (NEMOS) . Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD): revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part Ⅱ: attack therapy and long-term management. J Neurol , 2024 , 271 : 141- 176.
doi: 10.1007/s00415-023-11910-z
Jarius S , Aktas O , Ayzenberg I , Bellmann-Strobl J , Berthele A , Giglhuber K , Häußler V , Havla J , Hellwig K , Hümmert MW , Kleiter I , Klotz L , Krumbholz M , Kümpfel T , Paul F , Ringelstein M , Ruprecht K , Senel M , Stellmann JP , Bergh FT , Tumani H , Wildemann B , Trebst C , Neuromyelitis Optica Study Group (NEMOS) . Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD): revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part Ⅰ: diagnosis and differential diagnosis. J Neurol , 2023 , 270 : 3341- 3368.
doi: 10.1007/s00415-023-11634-0
Wingerchuk DM , Banwell B , Bennett JL , Cabre P , Carroll W , Chitnis T , de Seze J , Fujihara K , Greenberg B , Jacob A , Jarius S , Lana-Peixoto M , Levy M , Simon JH , Tenembaum S , Traboulsee AL , Waters P , Wellik KE , Weinshenker BG , International Panel for NMO Diagnosis . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology , 2015 , 85 : 177- 189.
doi: 10.1212/WNL.0000000000001729
Chinese Society of Neuroimmunology . Expert consensus on the detection of antibodies associated with autoimmune diseases of the central nervous system 2022. Zhonghua Shen Jing Ke Za Zhi, 2023 , 56 : 257- 268.
Fu Y , Bi J , Yan Y , Sun X , Li K , Kim SY , Han SM , Zhou L , Li R , Huang Q , Wang N , Lin A , Kim HJ , Qiu W . Rapid immunodot AQP4 assay for neuromyelitis optica spectrum disorder. JAMA Neurol , 2023 , 80 : 1105- 1112.
doi: 10.1001/jamaneurol.2023.2974
Paul F , Marignier R , Palace J , Arrambide G , Asgari N , Bennett JL , Cree BAC , De Sèze J , Fujihara K , Kim HJ , Hornby R , Huda S , Kissani N , Kleiter I , Kuwabara S , Lana-Peixoto M , Law L , Leite MI , Pandit L , Pittock SJ , Quan C , Ramanathan S , Rotstein D , Saiz A , Sato DK , Vaknin-Dembinsky A . International Delphi consensus on the management of AQP4-IgG+NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm , 2023 , 10 : e200124.
doi: 10.1212/NXI.0000000000200124
Aktas O , Smith MA , Rees WA , Bennett JL , She D , Katz E , Cree BAC , N-MOmentum Scientific Group and the N-MOmentum Study Investigators . Serum glial fibrillary acidic protein: aneuromyelitis optica spectrum disorder biomarker. Ann Neurol , 2021 , 89 : 895- 910.
doi: 10.1002/ana.26067
Schindler P , Grittner U , Oechtering J , Leppert D , Siebert N , Duchow AS , Oertel FC , Asseyer S , Kuchling J , Zimmermann HG , Brandt AU , Benkert P , Reindl M , Jarius S , Paul F , Bellmann-Strobl J , Kuhle J , Ruprecht K . Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation , 2021 , 18 : 105.
doi: 10.1186/s12974-021-02138-7
Aktas O , Hartung HP , Smith MA , Rees WA , Paul F , Marignier R , Bennett JL , Kim HJ , Weinshenker BG , Pittock SJ , Wingerchuk DM , Cutter G , She D , Gunsior M , Cimbora D , Katz E , Cree BA , N-MOmentum Study Investigators . Serum-neurofilament light chain levels at attack predict post attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry , 2023 , 94 : 757- 768.
doi: 10.1136/jnnp-2022-330412
Nie T , Blair HA . Inebilizumab: a review in neuromyelitis optica spectrum disorder. CNS Drugs , 2022 , 36 : 1133- 1141.
doi: 10.1007/s40263-022-00949-7
Pittock SJ , Berthele A , Fujihara K , Kim HJ , Levy M , Palace J , Nakashima I , Terzi M , Totolyan N , Viswanathan S , Wang KC , Pace A , Fujita KP , Armstrong R , Wingerchuk DM . Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med , 2019 , 381 : 614- 625.
doi: 10.1056/NEJMoa1900866
Wingerchuk DM , Fujihara K , Palace J , Berthele A , Levy M , Kim HJ , Nakashima I , Oreja-Guevara C , Wang KC , Miller L , Shang S , Sabatella G , Yountz M , Pittock SJ , PREVENT Study Group . Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol , 2021 , 89 : 1088- 1098.
doi: 10.1002/ana.26049
Palace J , Wingerchuk DM , Fujihara K , Berthele A , Oreja-Guevara C , Kim HJ , Nakashima I , Levy M , Terzi M , Totolyan N , Viswanathan S , Wang KC , Pace A , Yountz M , Miller L , Armstrong R , Pittock S , PREVENT Study Group . Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord , 2021 , 47 : 102641.
doi: 10.1016/j.msard.2020.102641
Sen S , Tuncer A , Terzi M , Bunul SD , Ozen-Acar P , Altunrende B , Ozakbas S , Tutuncu M , Uygunoglu U , Akman-Demir G , Karabudak R , Efendi H , Siva A . Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment. Mult Scler Relat Disord , 2023 , 79 : 104949.
doi: 10.1016/j.msard.2023.104949
Cree BAC , Bennett JL , Kim HJ , Weinshenker BG , Pittock SJ , Wingerchuk DM , Fujihara K , Paul F , Cutter GR , Marignier R , Green AJ , Aktas O , Hartung HP , Lublin FD , Drappa J , Barron G , Madani S , Ratchford JN , She D , Cimbora D , Katz E , N-MOmentum Study Investigators . Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet , 2019 , 394 : 1352- 1363.
doi: 10.1016/S0140-6736(19)31817-3
Rensel M , Zabeti A , Mealy MA , Cimbora D , She D , Drappa J , Katz E . Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ≥ 4 years in the N-MOmentum trial. Mult Scler , 2022 , 28 : 925- 932.
doi: 10.1177/13524585211047223
Howard JF Jr , Utsugisawa K , Benatar M , Murai H , Barohn RJ , Illa I , Jacob S , Vissing J , Burns TM , Kissel JT , Muppidi S , Nowak RJ , O'Brien F , Wang JJ , Mantegazza R , REGAIN Study Group . Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol , 2017 , 16 : 976- 986.
doi: 10.1016/S1474-4422(17)30369-1
Kim HJ , Nakashima I , Viswanathan S , Wang KC , Shang S , Miller L , Yountz M , Wingerchuk DM , Pittock SJ , Levy M , Berthele A , Totolyan N , Palace J , Barnett MH , Fujihara K , PREVENT Study Group . Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: a subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Mult Scler Relat Disord , 2021 , 50 : 102849.
doi: 10.1016/j.msard.2021.102849
Nakashima I , Nakahara J , Yokote H , Manabe Y , Okamura K , Hasegawa K , Fujihara K . Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. Ther Adv Neurol Disord , 2023 , 16 : 1- 13.
Agius MA , Klodowska-Duda G , Maciejowski M , Potemkowski A , Li J , Patra K , Wesley J , Madani S , Barron G , Katz E , Flor A . Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler , 2019 , 25 : 235- 245.
doi: 10.1177/1352458517740641
Flanagan EP , Levy M , Katz E , Cimbora D , Drappa J , Mealy MA , She D , Cree BAC . Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord , 2022 , 57 : 103352.
doi: 10.1016/j.msard.2021.103352
Bennett JL , Aktas O , Rees WA , Smith MA , Gunsior M , Yan L , She D , Cimbora D , Pittock SJ , Weinshenker BG , Paul F , Marignier R , Wingerchuk D , Cutter G , Green A , Hartung HP , Kim HJ , Fujihara K , Levy M , Katz E , Cree BAC , N-MOmentum Study Investigators . Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: an exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. EBioMedicine , 2022 , 86 : 104321.
doi: 10.1016/j.ebiom.2022.104321
Kim HJ , Aktas O , Patterson KR , Korff S , Kunchok A , Bennett JL , Weinshenker BG , Paul F , Hartung HP , Cimbora D , Smith MA , Mittereder N , Rees WA , She D , Cree BAC . Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism. Ann Clin Transl Neurol , 2023 , 10 : 2413- 2420.
doi: 10.1002/acn3.51911
Igawa T , Ishii S , Tachibana T , Maeda A , Higuchi Y , Shimaoka S , Moriyama C , Watanabe T , Takubo R , Doi Y , Wakabayashi T , Hayasaka A , Kadono S , Miyazaki T , Haraya K , Sekimori Y , Kojima T , Nabuchi Y , Aso Y , Kawabe Y , Hattori K . Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol , 2010 , 28 : 1203- 1207.
doi: 10.1038/nbt.1691
Yamamura T , Kleiter I , Fujihara K , Palace J , Greenberg B , Zakrzewska-Pniewska B , Patti F , Tsai CP , Saiz A , Yamazaki H , Kawata Y , Wright P , De Seze J . Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med , 2019 , 381 : 2114- 2124.
doi: 10.1056/NEJMoa1901747
Traboulsee A , Greenberg BM , Bennett JL , Szczechowski L , Fox E , Shkrobot S , Yamamura T , Terada Y , Kawata Y , Wright P , Gianella-Borradori A , Garren H , Weinshenker BG . Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol , 2020 , 19 : 402- 412.
doi: 10.1016/S1474-4422(20)30078-8
Kleiter I , Traboulsee A , Palace J , Yamamura T , Fujihara K , Saiz A , Javed A , Mayes D , Büdingen HV , Klingelschmitt G , Stokmaier D , Bennett JL . Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm , 2022 , 10 : e200071.
Lennon-Chrimes S , Baumann HS , Klingelschmitt G , Kou X , Anania VG , Ito H , von Budingen HC . Characterisation of the PK and PD of satralizumab, a recycling antibody, to Support Q4W dosing in patients with NMOSD. Neurology , 2020 , 94
Yamamura T , Weinshenker B , Yeaman MR , De Seze J , Patti F , Lobo P , von Büdingen HC , Kou X , Weber K , Greenberg B . Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord , 2022 , 66 : 104025.
doi: 10.1016/j.msard.2022.104025
Vu T , Ortiz S , Katsuno M , Annane D , Mantegazza R , Beasley KN , Aguzzi R , Howard JF Jr . Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol , 2023 , 270 : 3129- 3137.
doi: 10.1007/s00415-023-11617-1
Pittock SJ , Barnett M , Bennett JL , Berthele A , de Sèze J , Levy M , Nakashima I , Oreja-Guevara C , Palace J , Paul F , Pozzilli C , Yountz M , Allen K , Mashhoon Y , Kim HJ . Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol , 2023 , 93 : 1053- 1068.
doi: 10.1002/ana.26626 张锐, 陶永丽, 蒋晨阳, 刘凯, 许予明, 宋波. 奥法妥木单抗治疗视神经脊髓炎谱系疾病疗效分析 [J]. 中国现代神经疾病杂志, 2024, 24(6): 491-496. 史若琳, 高秀洁, 崔家宁, 邵妍, 谢璐霜, 刘毅. 5-羟色胺与帕金森病非运动症状研究进展 [J]. 中国现代神经疾病杂志, 2024, 24(6): 497-501. 李海峰. 在进入靶向治疗的时代激素仍然是重症肌无力治疗的基础 [J]. 中国现代神经疾病杂志, 2024, 24(5): 295-307. 黄瑀, 廖金池, 舒崖清. 抗N-甲基-D-天冬氨酸受体脑炎睡眠障碍研究进展 [J]. 中国现代神经疾病杂志, 2024, 24(5): 315-319. 刘彩云, 金涛. 树突状细胞在多发性硬化免疫治疗中的应用 [J]. 中国现代神经疾病杂志, 2024, 24(5): 320-330. 秦红玲, 李启慧, 卢意, 邱伟, 舒崖清. 抗接触蛋白相关蛋白-2抗体相关脑炎临床特征分析 [J]. 中国现代神经疾病杂志, 2024, 24(5): 340-345. 地址：天津市津南区吉兆路6号
邮编：300350
电话：022-59065611
E-mail：[email protected]
技术支持： 北京玛格泰克科技发展有限公司
 
推荐文章
考研的围巾  ·  阿尔泰山降水氢氧稳定同位素特征及水汽来源分析
1 周前
道上混的斑马  ·  臺灣大學數位人文研究中心
2 天前
不要命的汉堡包  ·  上海交通大学安泰经济与管理学院MBA项目
5 月前
文质彬彬的野马  ·  如何评价菲利普因扎吉的能力？为什么现在足坛几乎没有他这种类型的球员了？ - 知乎
2 年前
怕老婆的米饭  ·  金东区人民政府 历史沿革
2 年前
坏坏的路灯  ·  跟 Q5 沒關係！上汽奧迪 Audi Q5 e-tron 量產版出現中國工信部目錄！ - CarStuff 人車事
2 年前
朝气蓬勃的李子  ·  海贼王：小丑巴基果实觉醒，取代凯多成为四皇
2 年前
Link管理   ·   Sov5搜索   ·   小百科
小百科 - 百科知识指南